Form 4: Vigil Neuroscience CSO Disposes Options Post-Sanofi Merger

Vigil Neuroscience's Chief Science Officer, David L. F. Gray, disposed of stock options following the company's acquisition by Sanofi, converting them into cash and contingent value rights.

Summary

• Vigil Neuroscience, Inc. was acquired by Sanofi through its wholly-owned subsidiary, Vesper Acquisition Sub Inc., with the merger becoming effective on August 5, 2025.
• Vigil Neuroscience, Inc. now operates as a wholly-owned subsidiary of Sanofi.
• Shareholders of Vigil Neuroscience received $8.00 per share in cash at closing, plus one Contingent Value Right (CVR) per share, which offers the right to receive an additional $2.00 in cash upon the satisfaction of a specific clinical milestone.
• Chief Science Officer David L. F. Gray's outstanding unvested stock options were accelerated and fully vested at the effective time of the merger.
• These options were subsequently cancelled and converted into cash and CVRs, based on the difference between the $8.00 closing amount and their respective exercise prices.
• Options disposed by Mr. Gray included 125,000 shares at an exercise price of $3.39, 125,000 shares at $2.19, and 267,000 shares at $3.03.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, which is generally a positive liquidity event for shareholders and option holders, converting equity into cash and CVRs. The acceleration of unvested options is also a positive for the reporting person. While the company ceases to be independent, the transaction itself is a positive outcome for the acquired entity's stakeholders.

Positives

• Unvested stock options held by the Chief Science Officer were accelerated and fully vested as a result of the merger, providing immediate value.
• Option holders received cash and Contingent Value Rights (CVRs) for their disposed options, representing a liquidity event.
• The merger consideration of $8.00 cash per share plus a potential $2.00 CVR per share provided a clear and defined valuation for shareholders and option holders.

Negatives

• Vigil Neuroscience, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Sanofi.
• Stock options were cancelled, meaning the reporting person no longer holds equity options in the former public entity, although they were converted to cash and CVRs.

Future Outlook

The filing primarily reports the completed merger transaction and its immediate financial implications for an insider's equity holdings. It does not provide forward-looking statements regarding the combined entity's future performance or strategic plans beyond the contingent value right's clinical milestone.

Industry Context

This merger represents a common trend in the biotechnology and pharmaceutical industries, where larger pharmaceutical companies like Sanofi acquire smaller, specialized biotech firms such as Vigil Neuroscience. Such acquisitions are typically driven by the desire to expand drug pipelines, gain access to specific therapeutic areas, or acquire innovative technologies, thereby consolidating market presence and fostering growth.

Comparison to Industry Standards

• The acquisition of a biotech company by a major pharmaceutical firm like Sanofi is a standard industry practice for pipeline expansion and strategic growth.
• The inclusion of Contingent Value Rights (CVRs) in the merger consideration is a common mechanism in biotech M&A, used to bridge valuation gaps and share future clinical development risks or rewards, especially when key assets are still in clinical trials.
• The acceleration and vesting of unvested stock options upon a change of control, as seen in this transaction, is a standard provision in executive compensation plans within the industry, designed to align executive incentives during mergers and acquisitions.

Stakeholder Impact

• Shareholders: Received a defined cash value and potential future cash through CVRs for their shares, providing a clear exit and liquidity.
• Employees (including David L. F. Gray): Benefited from the acceleration and conversion of unvested stock options into cash and CVRs, providing a financial gain.
• Company (Vigil Neuroscience): Transitioned from an independent public entity to a wholly-owned subsidiary of Sanofi, integrating its operations and pipeline into a larger pharmaceutical organization.

Next Steps

• Satisfaction of the clinical milestone for the $2.00 Contingent Value Right (CVR) payment.

Key Dates

Keywords

Vigil Neuroscience, Sanofi, Merger, Acquisition, SEC Form 4, Stock Options, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals, David L. F. Gray, Officer Transaction